American pharmaceutical company Eli Lilly (LLY.US) announced on Wednesday that it has signed an agreement worth up to $1.12 billion with German startup Seamless Therapeutics to develop and commercialize treatments for hearing loss using the latter's gene editing platform.
Eli Lilly will be responsible for the entire development process from preclinical testing to commercialization

American pharmaceutical company Eli Lilly announced on Wednesday that it has signed an agreement worth up to $1.12 billion with German startup Seamless Therapeutics to develop and commercialize treatments for hearing loss using the latter's gene editing platform. Eli Lilly will be responsible for the entire development process from preclinical testing to commercialization

AASTOCKS

Health Care Select Sector SPDR

iShares US Pharma

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

SPDR S&P Health Equip

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Turn Therapeutics

SPDR S&P Biotech

Direxion Daily LLY Bull 2X Shares

VG Health

Invesco Nasdaq Biotechnology ETF

Sensei Biotherapeutics

Defiance Daily Target 2X Long LLY ETF

ESC NEUBASE THERAPEUTI

Eli Lilly signs agreement with gene editing startup Seamless involving up to $1.12 billion